This potential disconnect between AKT activation and 4E-BP1 activation provided rationale for investigating the effectiveness of simultaneously targeting both upstream and downstream of the PI3K/AKT/mTOR pathway in CLL. This evidence concerns the gene MTOR and B-cell chronic lymphocytic leukemia.